INTERLEUKIN-17INHIBITION WITH SECUKINUMAB IMPROVES SUDOMOTOR DYSFUNCTION IN PSORIATIC ARTHRITIS

ASHIT SYNGLE1,2, INDERJEET VERMA3, SUDEEP KAUR4, TANYA SYNGLE5

1Cardio-Rheuma and Healing Touch City Clinic, Chandigarh, 2Fortis Multi Specialty Hospital, Mohali, India, 3Maharishi Markandeshwar College of Pharmacy, M M University, Ambala, Haryana, India, 4Department of Kayachikitsa, Postgraduate School of Ayurveda and Research Mandi Gobindgarh, Punjab, India, 5Healing Touch Foundation, Chandigarh, India

Email: indupup@gmail.com

Received: 19 Sep 2017 Revised and Accepted: 11 Jan 2018

Case Study

INTRODUCTION

A skin and joint disease with multifactorial etiology, psoriasis affects 1-2% of the general population [1]. Typically PsA involves joints of the axial skeleton with an asymmetrical pattern. The spectrum of symptoms includes inflammatory changes in attachments of articular capsules, tendons, and ligaments to the bone surface [1]. The disease can have a diverse clinical course but usually, manifests as oligoarthritis [1]. Peripheral sympathetic autonomic dysfunction in psoriatic arthritis is known [2]. Secukinumab is an IgG1k fully monoclonal antibody selectively targeting interleukin-17A. It’s effect on sudomotor dysfunction in PsA has not yet been reported.

Keywords: Psoriatic arthritis, Sudomotor dysfunction, Secukinumab, Autonomic neuropathy, Psoriasis

Psoriatic arthritis (PsA) is a relapsing inflammatory disease, most commonly a seronegative oligoarthritis found in patients with psoriasis, characterized by the absence of rheumatoid factor in serum, with differentiation features of distal joint involvement and in extreme cases of arthritis mutilans (which is a destructive form of PsA). Cardiovascular autonomic and peripheral sympathetic neuropathy occurs in PsA. However, there is no specific treatment recommendation for autonomic neuropathy (AN) in psoriatic diseases. Secukinumab, a recently approved therapeutic advancement for psoriasis and psoriatic arthritis, is an immunoglobulin G (IgG) 1k fully monoclonal antibody that selectively inhibits the effector function of interleukin (IL)-17A. Its effect on sudomotor dysfunction in PsA has not yet been reported. This is the first reported observation of improvement in peripheral sympathetic autonomic neuropathy with secukinumab in PsA. We report a case of a 52-year-old male with PsA on methotrexate 15 mg/week for 9 m moths. In addition to severe joint pains and swelling for the last 9 mnoths. In addition to PsA, the patient had light-headedness and disturbed bowel movements suggestive of autonomic dysfunction. He is a teetotaler and a non-smoker. He is normotensive and non-diabetic and does not have thyroid dysfunction. He had an elevated erythrocyte sedimentation rate (ESR) of 73 mm/1st hr and high C-reactive protein (CRP) of 25 mg/dl and DAS-28 (Disease Activity Score in 28 joints) score was 6.3 (table 1). Radiographs are depicted in fig. 1. Symptoms of ANS were measured by asking a number of questions according to an easily administered instrument, known as a survey on sudomotor function in a case of PsA.

CASE REPORT

A 52-year-old gentleman with a 25 y history of PsA being treated with oral methotrexate 15 mg/week since 15 y reported with increased joint pains and swelling for the last 9 mnoths. In addition to PsA, the patient had light-headedness and disturbed bowel movements suggestive of autonomic dysfunction. He is a teetotaler and a non-smoker. He is normotensive and non-diabetic and does not have thyroid dysfunction. He had an elevated erythrocyte sedimentation rate (ESR) of 73 mm/1st hr and high C-reactive protein (CRP) of 25 mg/dl and DAS-28 (Disease Activity Score in 28 joints) score was 6.3 (table 1). Radiographs are depicted in fig. 1. Symptoms of ANS were measured by asking a number of questions according to an easily administered instrument, known as a survey of autonomic symptoms [5].

Fig. 1A: Radiograph of sacroiliac joints, subchondral sclerotic changes are seen in bilateral sacroiliac joints with preserved joint space (Grade II Sacroilitis). Fig. 1B: Radiographs of hand joints. Reduced bone density changes are seen in bilateral hands. Extensive Erosive Arthritis with loss of Joint space with Subchondral Bone Destruction and Sclerotic changes are seen in right 3rd PIP and DIP joints. Ankylosis changes are seen at right 2nd metacarpophalangeal, PIP and DIP joints. Similar ankylosis changes also seen at left 4th PIP Joint. Joint Space narrowing with subchondral sclerosis is seen at right 1st interphalangeal joint, 4th PIP joint with osteophytes formation. Similar changes also were seen at left 2nd, 3rd and 4th PIP and DIP joints. Erosive arthritic changes also were seen at B1/ trapeziometacarpal and 2nd carpometacarpal joints with subchondral sclerotic changes joint space narrowing with sclerotic changes is seen at right Interphalangeal joints, radioscaphoid joint and distal radioulnar joint.

The peripheral sympathetic autonomic function was measured by non-invasive device Sudoscan (Sudoscan Impeto Medical Device, ELS 01750010193 Paris, France) [6]. Sudoscan is a FDA approved device designed to perform the precise evaluation of sweat gland function based on sweat chloride concentrations through reverse iontophoresis and chronoamperometry. Through reverse iontophoresis, the device generates a voltage to the cathode and a
current (intensity of around 0.2 mA) between the anode and cathode proportional to chloride concentration. At low voltages (60 μS = no dysfunction; 60–40 μS = moderate dysfunction [6]). Sudomotor function test was performed before the initiation of treatment and after each treatment interval. Sudomotor function test showed marked abnormalities of peripheral sympathetic function (table 1 and fig. 2). No other cause of neuropathy was found from the detailed clinical history, physical examination and biochemical screening (serum vitamin B12 deficiency, Thyroid Function Tests (T3, T4, TSH), fasting blood sugar, HbA1c, HbsAg, Anti-HCV, HIV).

Table 1: Results of sudomotor function and clinical tests

<table>
<thead>
<tr>
<th>Variables</th>
<th>0 w</th>
<th>4 w</th>
<th>8 w</th>
<th>Normal value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudoscan (µs)</td>
<td>43</td>
<td>56</td>
<td>72</td>
<td>&gt;60</td>
</tr>
<tr>
<td>ESR (mm/1h)</td>
<td>73</td>
<td>25</td>
<td>10</td>
<td>0-10</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>25</td>
<td>6</td>
<td>5.10</td>
<td>&lt;6</td>
</tr>
<tr>
<td>DAS-28</td>
<td>6.3</td>
<td>4.73</td>
<td>2.42</td>
<td>&lt;2.5</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>2</td>
<td>1</td>
<td>0.1</td>
<td>--</td>
</tr>
</tbody>
</table>

ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, DAS-28; disease activity score of 28 joints, HAQ-DI; health assessment questionnaire.

Secukinumab 150 mg subcutaneous was added to MTX 15 mg/week on day 0, 7, 14, 21 and day 28 as a loading dose followed by maintenance dose of 150 mg once a month. After the first dose of Secukinumab 150 mg subcutaneous, there was a rapid improvement in autonomic symptoms and sudomotor dysfunction (fig. 2) and normal values were achieved after 8 w of treatment. ESR, CRP and DAS-28 scores were reduced (table 1) and autonomic symptoms disappeared after 8 w of secukinumab administration. After 4 and 8 w treatment with secukinumab, there was a great improvement in the quality of life assessed by HAQ-DI (table 1).

DISCUSSION

We have shown in this case with active psoriatic arthritis a significant improvement in inflammatory disease activity and sudomotor dysfunction along with resolution of autonomic symptoms after treatment with secukinumab. Syngle et al. in 2013 first described the involvement of autonomic dysfunction in PsA patients with 37.5 % having moderate sudomotor dysfunction [2]. Haligur et al. have reported sympathetic nervous system dysfunction in psoriasis but did not investigate sudomotor dysfunction [7].

The pathogenesis of peripheral sympathetic autonomic dysfunction and its treatment in PsA is still unknown. Sudomotor dysfunction reflects small fiber neuropathy, cardiovascular autonomic neuropathy and peripheral sympathetic autonomic neuropathy [6]. The early diagnosis and appropriate treatment of autonomic neuropathy are important because of higher risk of CV morbidity and mortality [8]. Cardiovascular autonomic neuropathy is a significant risk predictor for sudden cardiac death in autoimmune rheumatic diseases [9].

In the present case study, the index patient with active PsA had sympathedic dysfunction along with some autonomic symptoms.
Secukinumab, when added to methotrexate significantly, reduced the high disease activity, inflammation, autonomic symptoms and abnormal sudomotor dysfunction. Though symptoms of autonomic dysfunction may be absent or occur with varying frequency and intensity, sympathetic nervous system dysfunction can be detected non-invasively and is important to prevent severe consequences including myocardial infarction, arrhythmias and sudden cardiac death.

The role of proinflammatory cytokines, including TNF-α, IL-1, IL-6, IL-8, IL-10, IL-12, IL-17A and IL-23, has been demonstrated within the joint in psoriatic arthritis and relationship between cytokine levels and clinical arthritis severity demonstrated [10]. The proinflammatory cytokine Interleukin 17 (IL-17) has recently emerged as a key proinflammatory cytokine that orchestrates immune responses during infection, acute inflammation, allergy and autoimmune disease. It is secreted by immune cells such as Th17 cells, and its receptors are ubiquitously expressed. Th-17 cells and innate IL-17 producers have been shown to be important players of IL-17-induced effects in the joint [11]. IL-17, being a proinflammatory cytokine, in turn, acts on synovium, macrophages, dendritic cells, endothelial cells, chemokines, entheseal cells and osteoclasts [11].

IL-17 effects in PsA are mediated through IL-1, IL-6, IL-8, TNF-α, MMP-3, receptor activator of NFκB [12]. Blockage of IL-17 receptor (IL-17RA) with anti-IL-17 RA antibody (secukinumab) inhibited the production of IL-6, IL-8 and matrix metalloproteinase-3 (MMP-3) [13]. Overproduction of IL-17 can affect different parts of the body in PsA resulting in significant disability and poor quality of life [13]. Through the induction of other cytokines like IL-6, TNF-α and nitric oxide, IL-17 may also result in complications like accelerated atherosclerosis and autonomic dysfunction [12].

Both in ankylosing spondylitis and PsA, the cytokine-mediated inflammatory process may contribute to the autonomic abnormalities [2, 14]. On the other hand, there is also evidence for the contribution of the nervous system to inflammation [2, 14, 15]. Thus it is possible that the sudomotor dysfunction associated with PsA is likely to be immune-mediated and driven by the inflammatory state that characterizes the disease.

Hence treatment with IL-17A monoclonal antibody, secukinumab, through its IL-17RA blocking action with resultant immune-modulatory and anti-inflammatory effect can have beneficial effects on the sudomotor dysfunction of PsA.

**CONCLUSION**

To the best of our knowledge, this is the first case study to report the therapeutic impact of secukinumab on sudomotor dysfunction in active PsA. Although we were unable to investigate the mechanism of improvement of sympathetic dysfunction, our findings indicate that IL-17A blockade with secukinumab does have the immune-modulatory and anti-inflammatory potential as well as appears to exert a beneficial effect on sudomotor dysfunction in PsA. This case report suggests a reduction in sympathetic abnormalities of PsA.

**DECLARATION OF CONFLICT OF INTEREST**

No potential conflicts of interest relevant to this article were reported.

**ACKNOWLEDGEMENT**

We wish to thank the radiological expertise of Dr. Aman Deepak, MD, Radiology.

**AUTHORS CONTRIBUTIONS**

ASHIT SYNGLE: Patient assessment and case study designing

INDERJEET VERMA: Manuscript writing and sudomotor function testing

SUDEEP KAUR: Patient assessment

TANYA SYNGLE: Manuscript writing

**REFERENCES**


